![]() A Case of Cervical Lymphadenopathy After Vaccination Against COVID-19. Current Problems in Cancer: Case Reports. Case report of lymph node activation mimicking cancer progression: A false positive F18 FDG PET CT after COVID-19 vaccination. Lymphadenopathy after the Anti-COVID-19 Vaccine: Multiparametric Ultrasound Findings. doi: 10.1016/j.acra.2021.04.007.Ĭocco G, Delli Pizzi A, Fabiani S, Cocco N, Boccatonda A, Frisone A, et al. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Unexplained lymphadenopathy: evaluation and differential diagnosis. Mitigating the impact of coronavirus disease (COVID-19) vaccinations on patients undergoing breast imaging examinations: a pragmatic approach. Available from: Lehman CD, Lamb LR, D'Alessandro HA. Centers for Disease Control and Prevention, Centers for Disease Control and Prevention. Available from: Local reactions ae, and serious adverse events: Moderna COVID-19 vaccine. Centers for Disease Control and Prevention, Centers for Disease Control and Prevention Decem2021. Local reactions ae, and serious adverse events: Pfizer-BioNTech COVID-19 vaccine. Pfizer-BioNTech, la primera vacuna ARNm contra la COVID-19, parece segura y eficaz. WHO coronavirus (COVID-19) dashboard 2021. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. doi: 10.1016/j.clinimag.2020.11.054.Īkbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, et al. Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation. Keshavarz P, Rafiee F, Kavandi H, Goudarzi S, Heidari F, Gholamrezanezhad A. The immune system and COVID-19: Friend or foe? Life sciences. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T, et al. We found that imaging findings of LAP associated with vaccination were seen from the first day to two months after vaccination of the first or second dosage of different types of COVID-19 vaccines.Ĭonclusion: This review study can draw a broad perspective by focusing on patients with cancer, especially BC, for clinicians to proceed with the right approach at the right time without additional invasive measures and not to hold the necessary action in high-risk patients at the same time. The most common LAP locations were axillary (n = 540) and followed by axillary and supraclavicular (n = 271). We reviewed the LAP presentation after vaccination of first or second dosage of Pfizer-BioNTech (n = 754, 85.7%), Moderna (n = 38, 4.3%), Oxford-AstraZeneca (n = 39, 4.4%), Sputnik V (n = 1, 0.1%), Johnson & Johnson/Janssen (n = 1, 0.1%), CureVac (n = 1, 0.1%), and in 46 (5.3%) cases, the type of vaccine was not reported. ![]() Results: In total, 59 studies (n = 880 cases), including 412 (46.8%) females, 146 (16.6%) males, and 322 (36.6%) cases with unknown gender were reviewed. ![]() Keywords of literature search included “COVID-19”, “coronavirus disease”, “Vaccine”, and “Vaccination”, “LAP”, “Adverse event*”, “Lymph node”, “Cancer, breast”, and “Lymphadenopathy”. Methods: We conducted a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), Cochrane library, and Google Scholar. Background: With an increasing rate of lymphadenopathies (LAP) reported following COVID-19 vaccination with various vaccines’ types, which can mimic breast cancer (BC), a comprehensive review, can disclose some practical information about BC workup that reduces the incidence and mortality of the disease along with unnecessary steps.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |